Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma (Scientific Reports (2015) 5:11465) doi: 10.1038/srep11465);XI-006 induces potent p53-independent apoptosis in Ewing sarcoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pishas, Kathleen I ^a   Adwal, Alaknanda ^a   Neuhaus, Susan J ^b   Clayer, Mark T ^c   Farshid, Gelareh ^d   Staudacher, Alexander H ^b,e   Callen, David F ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Division of Tissue Pathology   (Australia)

^e CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4-NITROBENZODIFUROXAN; AMINE OXIDE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNA BINDING PROTEIN; EDIL3 PROTEIN, HUMAN; FLOTILLINS; GPSM2 PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HEG1 PROTEIN, HUMAN; HISTONE; KIF20A PROTEIN, HUMAN; KINESIN; MDM4 PROTEIN, HUMAN; MEMBRANE PROTEIN; MRE11A PROTEIN, HUMAN; NUCLEAR PROTEIN; OLAPARIB; ONCOPROTEIN; OXADIAZOLE DERIVATIVE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN P53; SIGNAL PEPTIDE; UTRN PROTEIN, HUMAN; UTROPHIN; XI-006;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BONE NEOPLASMS; CELL DIVISION; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; SARCOMA, EWING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CARRIER PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CYCLIC N-OXIDES; DNA DAMAGE; DNA-BINDING PROTEINS; HISTONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KINESIN; MEMBRANE PROTEINS; NUCLEAR PROTEINS; OXADIAZOLES; PHTHALAZINES; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEIN P53; UTROPHIN;

EID: 84935011020     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13328     Document Type: Erratum

References (56)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277-300 (2010).
2. Fletcher CDM, B. J., Hogendoorn, P. C. W. & Mertens, F. World Health Organization Classification of tumours and soft tissue of bone. 4th, IARC Press (Lyon 2013).
3. Danovi, D. et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24, 5835-5843 (2004).
4. Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18, 1239-1247 (2012).
5. Laurie, N. A. et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444, 61-66 (2006).
6. Valentin-Vega, Y. A., Barboza, J. A., Chau, G. P., El-Naggar, A. K. & Lozano, G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38, 1553-1562 (2007).
7. Bartel, F. et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117, 469-475 (2005).
8. Ito, M. et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 17, 416-426 (2011).
9. Duhamel, L. A. et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 60, 357-359 (2012).
10. Linares, L. K., Hengstermann, A., Ciechanover, A., Muller, S. & Scheffner, M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 100, 12009-12014 (2003).
11. Migliorini, D. et al. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 277, 7318-7323 (2002).
12. Reed, D. et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285, 10786-10796 (2010).
13. Bista, M. et al. On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS One 7, e37518 (2012).
14. Bernal, F. et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18, 411-422 (2010).
15. Verdine, G. L. & Hilinski, G. J. Stapled peptides for intracellular drug targets. Methods Enzymol 503, 3-33 (2012).
16. Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13, 83-96 (2013).
17. Gilkes, D. M. et al. Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol 28, 1999-2010 (2008).
18. Wang, H., Ma, X., Ren, S., Buolamwini, J. K. & Yan, C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 10, 69-79 (2011).
19. Pishas, K. I. et al. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res 74, 921-31 (2014).
20. Wynendaele, J. et al. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70, 9641-9649 (2010).
21. Pishas, K. I. et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 17, 494-504 (2011).
22. Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998).
23. Kapitzky, L. et al. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Molecular systems biology 6, 451 (2010).
24. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-5868 (1998).
25. Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S. & Chen, J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. Embo J 24, 3411-3422 (2005).
26. Klevernic, I. V., Morton, S., Davis, R. J. & Cohen, P. Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 418, 625-634 (2009).
27. Brenner, J. C. et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 72, 1608-1613 (2012).
28. Bryant, H. E. et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. Embo J 28, 2601-2615 (2009).
29. Neef, R. et al. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. The Journal of cell biology 162, 863-875 (2003).
30. Balamuth, N. J. & Womer, R. B. Ewing's sarcoma. Lancet Oncol 11, 184-192 (2010).
31. Yelamos, J., Farres, J., Llacuna, L., Ampurdanes, C. & Martin-Caballero, J. PARP-1 and PARP-2: New players in tumour development. American journal of cancer research 1, 328-346 (2011).
32. Prasad, S. C., Thraves, P. J., Bhatia, K. G., Smulson, M. E. & Dritschilo, A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 50, 38-43 (1990).
33. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
34. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361, 123-134 (2009).
35. Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat Cell Biol 16, 2-9 (2014).
36. Stracker, T. H. & Petrini, J. H. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 12, 90-103 (2011).
37. Daemen, A. et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 135, 505-517 (2012).
38. McPherson, L. A., Shen, Y. & Ford, J. M. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett 343, 217-223 (2014).
39. Vilar, E. et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71, 2632-2642 (2011).
40. Koppensteiner, R. et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS One 9, e100041 (2014).
41. Gaymes, T. J. et al. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 98, 1397-1406 (2013).
42. Suen, D. F., Norris, K. L. & Youle, R. J. Mitochondrial dynamics and apoptosis. Genes Dev 22, 1577-1590 (2008).
43. Frank, S. et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Developmental cell 1, 515-525 (2001).
44. Karbowski, M. et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. The Journal of cell biology 159, 931-938 (2002).
45. Langhorst, M. F., Reuter, A. & Stuermer, C. A. Scaffolding microdomains and beyond: the function of reggie/flotillin proteins. Cell Mol Life Sci 62, 2228-2240 (2005).
46. Lin, C. et al. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res 17, 3089-3099 (2011).
47. Song, L. et al. Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology 143, 995-1005 e1012 (2012).
48. Daire, V. & Pous, C. Kinesins and protein kinases: key players in the regulation of microtubule dynamics and organization. Arch Biochem Biophys 510, 83-92 (2011).
49. Corrigan, A. M. et al. Automated tracking of mitotic spindle pole positions shows that LGN is required for spindle rotation but not orientation maintenance. Cell Cycle 12, 2643-2655 (2013).
50. Hill, E., Clarke, M. & Barr, F. A. The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. Embo J 19, 5711-5719 (2000).
51. Taniuchi, K. et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 65, 105-112 (2005).
52. Yan, G. R. et al. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 12, 2391-2399 (2012).
53. Lobert, S., Vulevic, B. & Correia, J. J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35, 6806-6814 (1996).
54. Touqan, N. et al. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC clinical pathology 13, 32 (2013).
55. McEvoy, J. et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One 7, e42739 (2012).
56. Zhao, L., Wientjes, M. G. & Au, J. L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10, 7994-8004 (2004).